Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT-Reference-Cited by-同舟云学术

Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT

Published:2024-05-27 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Ye Yishan^ORCID,Labopin Myriam,Chen Jia,Wu Depei^ORCID,Gedde-Dahl Tobias,Blaise Didier^ORCID,Socie Gérard^ORCID,Forcade Edouard^ORCID,Salmenniemi Urpu,Maury Sébastien,Versluis Jurjen,Bazarbachi Ali^ORCID,Nagler Arnon,Brissot Eolia^ORCID,Li Lin,Luo Yi,Shi Jimin,Ciceri Fabio^ORCID,Huang He,Mohty Mohamad^ORCID,Gorin Norbert Claude^ORCID

Funder

National Natural Science Foundation of China

Zhejiang Province Public Welfare Technology Application Research Project

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-01072-0.pdf

Reference12 articles.

1. Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.

2. Pigneux A, Labopin M, Maertens J, Cordonnier C, Volin L, Socie G, et al. Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). Leukemia. 2015;29:2375–81.

3. van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, et al. Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia: a study by the International Berlin-Frankfurt-Munster Study Group. J Clin Oncol. 2023;41:2963–74.

4. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114:2489–96.

5. Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;13:46.